sglt2 inhibitors and glp-1 receptor agonists together Cardiovascular outcome studies in type 2 diabetes: Comparison between Cardiovascular benefits of SGLT2 inhibitors
Description
doi: 10.3389/fimmu.2023.1153915
[DOI] [PubMed] [Google Scholar] 54.Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F.E., Nauck M.A., Nissen S.E., Pocock S., Poulter N.R., Ravn L.S., et al
As with any medication, its critical to remember that treatment results vary from person to person
I'll you next time
H.MaesM.De AndradeN
